Company Information
USD
1.47
- (-2%)
NASDAQ:IOBT, IO BIOTECH, INC.
Industry: Biotechnology
End of Day: 18 April 2024 GMT-4
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Address
Ole Maaloes Vej 3
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. David V. Smith, M.B.A.
Director
Mr. Jack Bech Nielsen
Director
Ms. Kathleen Sereda Glaub, M.B.A.
Director
Ms. Amy Sullivan, M.B.A.
CFO
Dr. Helen Collins, M.D.
Director
Dr. Peter Hirth, PhD
Chairman of the Board/Director
Ms. Heidi Hunter
Director
Dr. Mai-Britt Zocca, PhD
CEO/Director/Founder/President
Dr. Christian Elling, PhD
Director
Dr. Qasim Ahmad, M.D.
Chief Medical Officer
Mr. Muhammad Al-Hajj
Chief Scientific Officer
Mr. Devin Whittemore Smith
General Counsel
Ownership
Institution Holdings
Lundbeckfond Invest A/S
21,851,920 (33.169%)
Vivo Capital, LLC
6,173,439 (9.371%)
Novo A/S
5,747,067 (8.723%)
Novo Holdings A/S
5,747,067 (8.723%)
HBM Healthcare Investments Ltd
3,999,431 (6.071%)
HBM Partners Cayman Ltd
3,944,492 (5.987%)
Samsara BioCapital, LLC
3,640,015 (5.525%)
Samsara BioCapital, LP
3,640,015 (5.525%)
Morgan Stanley - Brokerage Accounts
2,281,682 (3.463%)
Marshall Wace Asset Management Ltd
2,105,262 (3.196%)
Individual Holdings
Ms. Amy Sullivan
74,382 (0.113%)
Dr. Mai-Britt Zocca, PhD
37,391 (0.057%)
Mr. Brian Burkavage
11,500 (0.018%)
Mr. Devin Whittemore Smith
4,938 (0.008%)
Make Smart Investment Choices
8BIT Global Pte Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
